Cargando…

Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer

Postsurgical relapse remains a common issue for resectable gastric cancer (GC). Here, we investigated the efficacy and safety of an adjuvant treatment combining chemotherapy with cellular immunotherapy (CIT) using autologous natural killer cells, γδT cells, and cytokine‐induced killer cells in the t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yizhuo, Wang, Chang, Xiao, Huijie, Niu, Chao, Wu, Haitao, Jin, Haofan, Yao, Cheng, He, Hua, Tian, Huimin, Han, Fujun, Li, Dan, Han, Wei, Xu, Jianting, Chen, Jingtao, Cui, Jiuwei, Li, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5269688/ https://www.ncbi.nlm.nih.gov/pubmed/27790867 http://dx.doi.org/10.1002/cam4.942

Ejemplares similares

Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients
por: Qian, Lei, et al.
Publicado: (2016)

Corrigendum to “Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients”
por: Qian, Lei, et al.
Publicado: (2022)

Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer
por: Ding, Xiao, et al.
Publicado: (2015)

Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer
por: Khalil, Lana, et al.
Publicado: (2022)

Estimating the optimal rate of adjuvant chemotherapy utilization for stage III colon cancer
por: Karim, Safiya, et al.
Publicado: (2019)

In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells
por: Niu, Chao, et al.
Publicado: (2015)

Significant benefits of adding neoadjuvant chemotherapy before concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized controlled trials
por: Wang, Mengmeng, et al.
Publicado: (2016)

Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy
por: Bhave, Prachi, et al.
Publicado: (2023)

The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma
por: Dibajnia, Pooya, et al.
Publicado: (2023)

The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients
por: Hsieh, Mei‐Chin, et al.
Publicado: (2016)

Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients: A prospective cohort study
por: Jongeneel, Gabrielle, et al.
Publicado: (2021)

Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction
por: Wang, Shixiang, et al.
Publicado: (2019)

Adjuvant radiotherapy and chemotherapy improve survival in patients with pancreatic adenocarcinoma receiving surgery: adjuvant chemotherapy alone is insufficient in the era of intensity modulation radiation therapy
por: Hsieh, Mao‐Chih, et al.
Publicado: (2018)

Stratification of Stage III colon cancer may identify a patient group not requiring adjuvant chemotherapy
por: Malik, Yasir G., et al.
Publicado: (2020)

Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer
por: Kim, Jin K, et al.
Publicado: (2022)

Impact of adjuvant chemotherapy on outcomes in appendiceal cancer
por: Kolla, Bhaskar C., et al.
Publicado: (2020)

Epstein–Barr virus infection is associated with clinical characteristics and poor prognosis of multiple myeloma
por: Xia, Bing, et al.
Publicado: (2019)

Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer
por: Chang, Alex Yuang-Chi, et al.
Publicado: (2016)

Postoperative Adjuvant Chemoradiotherapy on the Survival of Stage III Gastric Cancer
por: Li, Chao, et al.
Publicado: (2022)

A phase III study of adjuvant chemotherapy in patients with completely resected, node-negative non–small cell lung cancer (JCOG 0707)
por: Kunitoh, Hideo, et al.
Publicado: (2020)

Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population‐based series and a randomized phase III study on adjuvant chemotherapy
por: Boye, Kjetil, et al.
Publicado: (2016)

Predictive impact of the inflammation‐based indices in colorectal cancer patients with adjuvant chemotherapy
por: Tao, Yong, et al.
Publicado: (2018)

Is there a progression‐free survival benefit of first‐line crizotinib versus standard chemotherapy and second‐line crizotinib in ALK‐positive advanced lung adenocarcinoma? A retrospective study of Chinese patients
por: Cui, Shaohua, et al.
Publicado: (2016)

Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer
por: Bai, Rilan, et al.
Publicado: (2020)

Dehydroeffusol inhibits hypoxia-induced epithelial–mesenchymal transition in non-small cell lung cancer cells through the inactivation of Wnt/β-catenin pathway
por: Wei, Haitao, et al.
Publicado: (2020)

Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma
por: Niu, Chao, et al.
Publicado: (2016)

Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)
por: Singh, Preet Paul, et al.
Publicado: (2016)

Knockdown of CRAD suppresses the growth and promotes the apoptosis of human lung cancer cells via Claudin 4
por: Cui, Anfang, et al.
Publicado: (2020)

Delayed initiation of adjuvant chemotherapy in older women with breast cancer
por: Smith‐Graziani, Demetria, et al.
Publicado: (2020)

Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC
por: Sluiter, Nina R., et al.
Publicado: (2018)

Neoadjuvant Versus Adjuvant Chemotherapy for Resectable Metastatic Colon Cancer in Non-academic and Academic Programs
por: Hao, Zhonglin, et al.
Publicado: (2022)

Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia
por: Wang, Zong-Han, et al.
Publicado: (2023)

Adjuvant chemotherapy for early-stage cervical cancer
por: Asano, Hiroshi, et al.
Publicado: (2016)

The value of adjuvant chemotherapy in stage II/III colorectal signet ring cell carcinoma
por: Zhao, Zhuang, et al.
Publicado: (2020)

Prognostic factors of adjuvant chemotherapy discontinuation among stage III colon cancer patients: A survey of medical oncologists and a systematic review and meta‐analysis
por: Boyne, Devon J., et al.
Publicado: (2020)

Treatment times in breast cancer patients receiving neoadjuvant vs adjuvant chemotherapy: Is efficiency a benefit of preoperative chemotherapy?
por: Melchior, Nicole M., et al.
Publicado: (2020)

Immunohistochemistry‐Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer
por: Li, Yaqi, et al.
Publicado: (2020)

Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma
por: He, Xiran, et al.
Publicado: (2020)

Impact of adjuvant chemotherapy on the survival of patients with breast cancer diagnosed by screening
por: Zarcos‐Pedrinaci, Irene, et al.
Publicado: (2019)

Improving survival of stage II‐III primary gastric signet ring cell carcinoma by adjuvant chemoradiotherapy
por: Li, Yang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jn7uim1m23a889hnfim0sjieqp